Gefitinib News and Research

RSS
Gefitinib is approved by the Food and Drug Administration (FDA) to treat locally advanced or metastatic non-small cell lung cancer (NSCLC) that has not gotten better after treatment with other chemotherapy. It is available only as part of a special program called the Iressa Access Program. Gefitinib is also being studied in the treatment of other types of cancer.

Gefitinib is an anilinoquinazoline with antineoplastic activity. Gefitinib inhibits the catalytic activity of numerous tyrosine kinases including the epidermal growth factor receptor (EGFR), which may result in inhibition of tyrosine kinase-dependent tumor growth. Specifically, this agent competes with the binding of ATP to the tyrosine kinase domain of EGFR, thereby inhibiting receptor autophosphorylation and resulting in inhibition of signal transduction. Gefitinib may also induce cell cycle arrest and inhibit angiogenesis.
Boehringer Ingelheim reports positive results from afatinib phase IIb/III LUX-Lung 1 trial in advanced NSCLC

Boehringer Ingelheim reports positive results from afatinib phase IIb/III LUX-Lung 1 trial in advanced NSCLC

Targeted therapies could treat a broad range of cancers: Research

Targeted therapies could treat a broad range of cancers: Research

Enzon presents data on three investigational mRNA antagonists at EORTC-NCI-AACR Symposium

Enzon presents data on three investigational mRNA antagonists at EORTC-NCI-AACR Symposium

Study: EGFR inhibtion may help treat triple negative breast cancer

Study: EGFR inhibtion may help treat triple negative breast cancer

Gefitinib exhibits potential as chemoprevention agent for pancreatic cancer

Gefitinib exhibits potential as chemoprevention agent for pancreatic cancer

AVEO third quarter total collaboration revenues increase to $6.2 million

AVEO third quarter total collaboration revenues increase to $6.2 million

Enzon data on LNA technology platform accepted for presentation at EORTC-NCI-AACR Symposium

Enzon data on LNA technology platform accepted for presentation at EORTC-NCI-AACR Symposium

Erlotinib improves progression-free survival as first-line therapy in advanced lung cancer

Erlotinib improves progression-free survival as first-line therapy in advanced lung cancer

New phase 2 study shows first-line promise of lung cancer drug PF-299

New phase 2 study shows first-line promise of lung cancer drug PF-299

Afatinib benefits lung cancer patients whose cancer progressed after treatment with EGFR inhibitors

Afatinib benefits lung cancer patients whose cancer progressed after treatment with EGFR inhibitors

Final results from landmark trial confirm survival benefits of EGFR mutations in lung cancer

Final results from landmark trial confirm survival benefits of EGFR mutations in lung cancer

Boehringer Ingelheim announces results from afatinib clinical trials at 35th ESMO

Boehringer Ingelheim announces results from afatinib clinical trials at 35th ESMO

First-line treatment with erlotinib drug improves progression-free survival in patients with advanced lung cancer

First-line treatment with erlotinib drug improves progression-free survival in patients with advanced lung cancer

AVEO regains global rights for development, commercialization of AV-299 anti-HGF antibody candidate

AVEO regains global rights for development, commercialization of AV-299 anti-HGF antibody candidate

Boehringer Ingelheim commences afatinib Phase III clinical trial in advanced breast cancer

Boehringer Ingelheim commences afatinib Phase III clinical trial in advanced breast cancer

AVEO second-quarter total revenues increase to $15.6 million

AVEO second-quarter total revenues increase to $15.6 million

AVEO's initiation of SCH 900105 Phase 2 trial in non-small cell lung cancer triggers $8.5M milestone payment

AVEO's initiation of SCH 900105 Phase 2 trial in non-small cell lung cancer triggers $8.5M milestone payment

Boehringer Ingelheim to present new data on BIBW 2992 for NSCLC and head-and-neck cancer at ASCO 2010

Boehringer Ingelheim to present new data on BIBW 2992 for NSCLC and head-and-neck cancer at ASCO 2010

Clovis Oncology, Avila Therapeutics announce development agreement for NSCLC EMSI program

Clovis Oncology, Avila Therapeutics announce development agreement for NSCLC EMSI program

Approval of personalized therapy for lung cancer in Europe will change way of treatment

Approval of personalized therapy for lung cancer in Europe will change way of treatment